Evidence map›Paper›PMID 28467814›Full record

ArticleOncotarget2017

Contribution of macrophages in the contrast loss in iron oxide-based MRI cancer cell tracking studies.

Pierre Danhier, Gladys Deumer, Nicolas Joudiou, Caroline Bouzin, Philippe Levêque, Vincent Haufroid, Bénédicte F Jordan, Olivier Feron, Pierre Sonveaux, Bernard Gallez

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. A primer onFrontiers in medicine · 2023
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Pierre DanhierLouvain Drug Research Institute, Biomedical Magnetic Resonance Research Group, Université Catholique de Louvain (UCL), Brussels, Belgium.
Gladys DeumerLouvain Center for Toxicology and Applied Pharmacology, Université Catholique de Louvain (UCL), Brussels, Belgium.
Nicolas JoudiouLouvain Drug Research Institute, Biomedical Magnetic Resonance Research Group, Université Catholique de Louvain (UCL), Brussels, Belgium.
Caroline BouzinInstitut de Recherche Expérimentale et Clinique (IREC), IREC Imaging Platform, Université Catholique de Louvain (UCL), Brussels, Belgium.
Philippe LevêqueLouvain Drug Research Institute, Biomedical Magnetic Resonance Research Group, Université Catholique de Louvain (UCL), Brussels, Belgium.
Vincent HaufroidLouvain Center for Toxicology and Applied Pharmacology, Université Catholique de Louvain (UCL), Brussels, Belgium.
Bénédicte F JordanLouvain Drug Research Institute, Biomedical Magnetic Resonance Research Group, Université Catholique de Louvain (UCL), Brussels, Belgium.
Olivier FeronInstitut de Recherche Expérimentale et Clinique (IREC), Pole of Pharmacology, Université Catholique de Louvain (UCL), Brussels, Belgium.
Pierre SonveauxInstitut de Recherche Expérimentale et Clinique (IREC), Pole of Pharmacology, Université Catholique de Louvain (UCL), Brussels, Belgium.
Bernard GallezLouvain Drug Research Institute, Biomedical Magnetic Resonance Research Group, Université Catholique de Louvain (UCL), Brussels, Belgium.
UCLouvain · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Magnetic resonance imaging (MRI) cell tracking of cancer cells labeled with superparamagnetic iron oxides (SPIO) allows visualizing metastatic cells in preclinical models. However, previous works showed that the signal void induced by SPIO on T2(*)-weighted images decreased over time. Here, we aim at characterizing the fate of iron oxide nanoparticles used in cell tracking studies and the role of macrophages in SPIO metabolism.In vivo MRI cell tracking of SPIO positive 4T1 breast cancer cells revealed a quick loss of T2* contrast after injection. We next took advantage of electron paramagnetic resonance (EPR) spectroscopy and inductively coupled plasma mass spectroscopy (ICP-MS) for characterizing the evolution of superparamagnetic and non-superparamagnetic iron pools in 4T1 breast cancer cells and J774 macrophages after SPIO labeling. These in vitro experiments and histology studies performed on 4T1 tumors highlighted the quick degradation of iron oxides by macrophages in SPIO-based cell tracking experiments.In conclusion, the release of SPIO by dying cancer cells and the subsequent uptake of iron oxides by tumor macrophages are limiting factors in MRI cell tracking experiments that plead for the use of (MR) reporter-gene based imaging methods for the long-term tracking of metastatic cells.

Indexed as

AnimalsCell Line, TumorCell TrackingContrast MediaFemaleFerric CompoundsMacrophagesMagnetic Resonance ImagingMagnetite NanoparticlesMammary Neoplasms, ExperimentalMiceMice, Inbred BALB CContrast MediaFerric Compoundsferric oxideMagnetite Nanoparticlescancer metastasiscell trackingEPRiron oxidesMRI

Identifiers

PMID28467814
PMCPMC5503579
OpenAlexW2606354190

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.